(Reuters) – The U.S. Food and Drug Administration on Tuesday approved Pfizer’s RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
(Reporting by Sneha S K; Editing by Alan Barona)
